metformin has been researched along with Parkinson Disease in 22 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI." | 8.12 | Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022) |
| "Metformin treatment caused astrocytes to alter reactive genes in a PD animal model." | 5.56 | Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. ( Choi, JH; Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, TG; Park, HY; Rhee, M; Ryu, YK; Seo, YJ, 2020) |
| "Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI." | 4.12 | Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. ( Duijn, CMV; Fernandes, M; Ghose, U; Launer, LJ; Li, QS; Linden, AB; Molero, Y; Nevado-Holgado, AJ; Newby, D; Sproviero, W; Winchester, L, 2022) |
| "Metformin was able to inhibit depressive-like behavior and increase signaling pathway proteins, transcription factors and autophagosome-forming proteins, thus inducing autophagy in both the hippocampus and the substantia nigra." | 1.72 | Metformin improves depressive-like behavior in experimental Parkinson's disease by inducing autophagy in the substantia nigra and hippocampus. ( da Silva, RS; de Melo, MG; de Paiva, IHR; do Nascimento, MIX; Duarte-Silva, EP; Mendonça, IP; Peixoto, CA, 2022) |
| "Metformin treatment caused astrocytes to alter reactive genes in a PD animal model." | 1.56 | Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. ( Choi, JH; Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, TG; Park, HY; Rhee, M; Ryu, YK; Seo, YJ, 2020) |
| "Metformin is a medication that is widely prescribed for the management of type 2 diabetes." | 1.48 | Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease. ( Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK, 2018) |
| "Following genetic screening of Parkinson's disease patients and healthy controls, we also report the first TRAP1 mutation leading to complete loss of functional protein in a patient with late onset Parkinson's disease." | 1.46 | Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease. ( Bobbili, DR; Brockmann, K; Bus, C; Carvajal Berrio, DA; Fitzgerald, JC; Gasser, T; Glaab, E; Hauser, AK; Krüger, R; Kübler, M; Lewin, R; Madlung, J; Martins, LM; Maurer, B; May, P; Nordheim, A; Picard, D; Riess, O; Schenke-Layland, K; Schindler, KM; Schulte, C; Schwarz, LM; Sharma, M; Vartholomaiou, E; Wüst, R; Zimprich, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 12 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Agostini, F | 1 |
| Masato, A | 1 |
| Bubacco, L | 1 |
| Bisaglia, M | 1 |
| Mendonça, IP | 1 |
| de Paiva, IHR | 1 |
| Duarte-Silva, EP | 1 |
| de Melo, MG | 1 |
| da Silva, RS | 1 |
| do Nascimento, MIX | 1 |
| Peixoto, CA | 1 |
| Newby, D | 1 |
| Linden, AB | 1 |
| Fernandes, M | 1 |
| Molero, Y | 1 |
| Winchester, L | 1 |
| Sproviero, W | 1 |
| Ghose, U | 1 |
| Li, QS | 1 |
| Launer, LJ | 1 |
| Duijn, CMV | 1 |
| Nevado-Holgado, AJ | 1 |
| Kakoty, V | 1 |
| Kc, S | 1 |
| Yang, CH | 1 |
| Dubey, SK | 1 |
| Taliyan, R | 1 |
| Xie, Y | 1 |
| Wang, J | 1 |
| Jiang, J | 1 |
| Liu, F | 1 |
| Zhang, Y | 1 |
| Gopar-Cuevas, Y | 1 |
| Saucedo-Cardenas, O | 1 |
| Loera-Arias, MJ | 1 |
| Montes-de-Oca-Luna, R | 1 |
| Rodriguez-Rocha, H | 1 |
| Garcia-Garcia, A | 1 |
| Sardoiwala, MN | 1 |
| Srivastava, AK | 1 |
| Kaundal, B | 1 |
| Karmakar, S | 1 |
| Choudhury, SR | 1 |
| Paudel, YN | 1 |
| Angelopoulou, E | 1 |
| Piperi, C | 1 |
| Shaikh, MF | 1 |
| Othman, I | 1 |
| Saewanee, N | 1 |
| Praputpittaya, T | 1 |
| Malaiwong, N | 1 |
| Chalorak, P | 1 |
| Meemon, K | 1 |
| Ryu, YK | 2 |
| Go, J | 2 |
| Park, HY | 2 |
| Choi, YK | 1 |
| Seo, YJ | 1 |
| Choi, JH | 1 |
| Rhee, M | 1 |
| Lee, TG | 2 |
| Lee, CH | 2 |
| Kim, KS | 2 |
| Cardoso, S | 1 |
| Moreira, PI | 1 |
| Mor, DE | 1 |
| Sohrabi, S | 1 |
| Kaletsky, R | 1 |
| Keyes, W | 1 |
| Tartici, A | 1 |
| Kalia, V | 1 |
| Miller, GW | 1 |
| Murphy, CT | 1 |
| Kang, H | 1 |
| Khang, R | 1 |
| Ham, S | 1 |
| Jeong, GR | 1 |
| Kim, H | 2 |
| Jo, M | 1 |
| Lee, BD | 1 |
| Lee, YI | 1 |
| Jo, A | 1 |
| Park, C | 1 |
| Seo, J | 1 |
| Paek, SH | 1 |
| Lee, YS | 1 |
| Choi, JY | 1 |
| Lee, Y | 1 |
| Shin, JH | 1 |
| Brakedal, B | 1 |
| Flønes, I | 1 |
| Reiter, SF | 1 |
| Torkildsen, Ø | 1 |
| Dölle, C | 1 |
| Assmus, J | 1 |
| Haugarvoll, K | 2 |
| Tzoulis, C | 2 |
| Choi, DH | 1 |
| Kim, YH | 1 |
| Hwang, JH | 1 |
| Noh, JR | 1 |
| Fitzgerald, JC | 2 |
| Zimprich, A | 2 |
| Carvajal Berrio, DA | 1 |
| Schindler, KM | 1 |
| Maurer, B | 1 |
| Schulte, C | 1 |
| Bus, C | 1 |
| Hauser, AK | 1 |
| Kübler, M | 1 |
| Lewin, R | 1 |
| Bobbili, DR | 1 |
| Schwarz, LM | 1 |
| Vartholomaiou, E | 1 |
| Brockmann, K | 1 |
| Wüst, R | 1 |
| Madlung, J | 1 |
| Nordheim, A | 1 |
| Riess, O | 1 |
| Martins, LM | 1 |
| Glaab, E | 1 |
| May, P | 2 |
| Schenke-Layland, K | 1 |
| Picard, D | 1 |
| Sharma, M | 2 |
| Gasser, T | 1 |
| Krüger, R | 2 |
| Reddy Bobbili, D | 1 |
| Gaare, JJ | 1 |
| Nido, GS | 1 |
| Sztromwasser, P | 1 |
| Knappskog, PM | 1 |
| Dahl, O | 1 |
| Lund-Johansen, M | 1 |
| Alves, G | 1 |
| Tysnes, OB | 1 |
| Johansson, S | 1 |
| Gantois, I | 1 |
| Popic, J | 1 |
| Khoutorsky, A | 1 |
| Sonenberg, N | 1 |
| Pupyshev, AB | 1 |
| Korolenko, TA | 1 |
| Tikhonova, MA | 1 |
| Jakova, E | 1 |
| Lee, JS | 1 |
| Wahlqvist, ML | 1 |
| Lee, MS | 1 |
| Hsu, CC | 1 |
| Chuang, SY | 1 |
| Lee, JT | 1 |
| Tsai, HN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for metformin and Parkinson Disease
| Article | Year |
|---|---|
Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges.
Topics: Animals; Autophagy; Biological Availability; Drug Repositioning; Humans; Metformin; Neuroprotective | 2021 |
Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Parkinso | 2023 |
Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
Topics: Animals; Autophagy; Behavior, Animal; Dopaminergic Neurons; Encephalitis; Humans; Hypoglycemic Agent | 2020 |
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Insul | 2020 |
Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.
Topics: Animals; Autistic Disorder; Disease Models, Animal; Fragile X Mental Retardation Protein; Fragile X | 2019 |
[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy].
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Clinical Trials as To | 2016 |
16 other studies available for metformin and Parkinson Disease
| Article | Year |
|---|---|
Metformin improves depressive-like behavior in experimental Parkinson's disease by inducing autophagy in the substantia nigra and hippocampus.
Topics: Animals; Antidepressive Agents; Autophagy; Disease Models, Animal; Hippocampus; Hypoglycemic Agents; | 2022 |
Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Mid | 2022 |
Exploring the Epigenetic Regulated Modulation of Fibroblast Growth Factor 21 Involvement in High-Fat Diet Associated Parkinson's Disease in Rats.
Topics: Animals; Diet, High-Fat; Epigenesis, Genetic; Insulin Resistance; Metformin; Parkinson Disease; Rats | 2023 |
Metformin and Trehalose-Modulated Autophagy Exerts a Neurotherapeutic Effect on Parkinson's Disease.
Topics: Aged; Animals; Autophagy; Dopamine; Humans; Metformin; Mice; Mice, Inbred C57BL; Neuroblastoma; Park | 2023 |
Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson's disease model.
Topics: alpha-Synuclein; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Humans; Indoles; Metformin; | 2020 |
Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in C. elegans model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis eleg | 2021 |
Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging.
Topics: Aging; Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Female; Male; Metformin; Mice, | 2020 |
Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria.
Topics: Amino Acids, Branched-Chain; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disea | 2020 |
Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.
Topics: Activating Transcription Factor 2; Animals; Brain; Cell Line, Tumor; Cell Survival; Cyclic AMP Respo | 2017 |
Glitazone use associated with reduced risk of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; D | 2017 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ma | 2018 |
Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
Topics: Adenosine Triphosphate; Apoptosis; Case-Control Studies; Cells, Cultured; Fibroblasts; High-Temperat | 2017 |
Reply: No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.
Topics: HSP90 Heat-Shock Proteins; Humans; Metformin; Mitochondria; Mutation; Parkinson Disease | 2018 |
No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.
Topics: HSP90 Heat-Shock Proteins; Humans; Metformin; Mitochondria; Mutation; Parkinson Disease | 2018 |
Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field.
Topics: alpha-Synuclein; Caffeine; Electricity; Electrophoresis; Humans; Metformin; Models, Chemical; Nanopo | 2017 |
Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; M | 2012 |